The company's founder is Dr. Adrian Harel, an experienced neurobiologist with an impressive track record in leadership of early-stage drug discovery companies and business management. His collaboration with renowned experts in medicinal chemistry promises to generate a successful pipeline of innovative therapeutic molecules and diagnostic biomarkers.
Medicortex's founder, Dr. Adrian Harel, has assembled an outstanding SAB to ensure that every aspect of pharmaceutical therapy and diagnostic kit development is handled with the utmost professionalism and scientific precision. It should be noted that Dr. Harel designed Medicortex's pipeline of 12 chemically-verified compounds, and he will be intimately involved in not only administration, but with R&D as well.
MD, PhD Mårten Kvist is working with Medicortex Finland Oy as Medical Director. Dr. Kvist has decades of experience in general practice and scientific work in medicine, having held positions as Adjunct Professor in two major universities in Finland.
Dr. Lasse Välimaa, MSc, PhD, is the company's head of research and development. He has vast experience as a researcher in biotechnology and especially in diagnostics at the university of Turku and as a medical writer.
Our new CFO is KLT-accountant Marjukka Pentti. Also a partner and member of the board in Tili-Vinkki Oy.
Prof. Heikki Rauvala - Chairman of the SAB, a research director at the Neuroscience Center of University of Helsinki. Dr. Rauvala has published 213 frequently cited publications relating to his primary research interests; development, plasticity and regeneration of the central nervous system; injuries of the central nervous system; behavioral disorders.
Academy Prof. Asla Pitkänen - Prof. of Neurobiology at the University of Eastern Finland. For the past decade, Dr. Pitkänen has focused her research on Post-TBI Epilepsy, and is considered one of the world's top PTE experts. As such, she has exceptional expertise in analysis of secondary brain injury.
Prof. Risto Roine - Head of neurology at Turku University Hospital and national coordinator for an EU Biomed project with a 2.2-million-euro budget. Dr. Roine has been a Principle Investigator in 15 studies relating to secondary neurological damage and its treatment.
Prof. James Fawcett - Chairman of the Cambridge University Centre for Brain Repair since 2001. Dr. Fawcett has an illustrious career in neurobiology. He has managed several EU Framework 7 studies, including one with a nearly 10-million-euro budget.
Chariman of the Board - Dr. Adrian Harel
Member Associate Professor Mårten Kvist, MD, PhD, Medical Director
Member Tom Palenius, Senior Advisor, Turku Science Park Oy & Head of Operations, Life Science Accelerator.